La Jolla Pharmaceutical Company
Quick facts
Phase 3 pipeline
- LJPC-501 · Immunology / Inflammation
LJPC-501 is a recombinant human C5a receptor antagonist that blocks complement activation and reduces inflammatory cell recruitment.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- La Jolla Pharmaceutical Company portfolio CI brief
- La Jolla Pharmaceutical Company pipeline updates RSS
Frequently asked questions about La Jolla Pharmaceutical Company
What is La Jolla Pharmaceutical Company's pipeline?
La Jolla Pharmaceutical Company has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include LJPC-501.
Related
- Sector hub: All tracked pharma companies